MGO One Seven LLC Sells 14,504 Shares of Zoetis Inc. $ZTS

Posted by George Bondi on Nov 8th, 2026

MGO One Seven LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 63.5% in the third quarter, Holdings Channel reports. The firm owned 8,351 shares of the company’s stock after selling 14,504 shares during the quarter. MGO One Seven LLC’s holdings in Zoetis were worth $583,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wealthfront Advisers LLC boosted its position in shares of Zoetis by 80.2% during the second quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after purchasing an additional 33,873 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Zoetis by 16.7% in the 1st quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after buying an additional 23,687 shares during the period. Diamond Hill Capital Management LLC Investment Advisor increased its position in shares of Zoetis by 21.5% in the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after buying an additional 629,974 shares in the last quarter. Nykredit A S bought a new stake in shares of Zoetis in the 2nd quarter valued at $10,042,000. Finally, Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter valued at $302,601,000. Institutional investors own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Adjusted EPS of $1.75 topped the $1.51 consensus, while revenue of $2.39 billion exceeded expectations of $2.30 billion. Zoetis also raised its full-year 2026 profit outlook. Zoetis Lifts Annual Outlook While Braces For Cautious Pet Economy
Positive Sentiment: Livestock revenue grew 7% to $797 million, helping offset softness in companion-animal products. Jefferies also raised its price target to $85 from $83. Zoetis: 3 Key Takeaways for Long-Term Investors
Negative Sentiment: Investors appear focused on ongoing pressure in the pet-health business: owners are cutting back on veterinary visits, and Zoetis is taking a cautious view of 2027. Competitive pressures and margin headwinds also weigh on the outlook. Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall ZTS Q3 2026 deep dive: Competitive pressures and margin headwinds weigh on outlook
Negative Sentiment: Despite beating estimates, quarterly revenue declined 1.3% year over year, reinforcing concerns that strength in livestock may not fully offset weaker companion-animal demand. Zoetis reports third-quarter results

Wall Street Analyst Weigh In

Several brokerages recently commented on ZTS. Leerink Partners dropped their price objective on Zoetis from $95.00 to $80.00 and set a “market perform” rating on the stock in a research note on Monday, July 13th. Citigroup decreased their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings upgraded Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, October 29th. Morgan Stanley lowered their price target on Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a report on Thursday, October 29th. Finally, The Goldman Sachs Group initiated coverage on Zoetis in a research report on Friday, October 16th. They set a “neutral” rating and a $74.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $101.25.

Get Our Latest Report on ZTS

Zoetis Stock Down 3.2%

Zoetis stock opened at $79.50 on Friday. The stock has a market capitalization of $32.85 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.17 and a beta of 0.67. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $132.49. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a 50 day moving average of $75.68 and a 200-day moving average of $92.60.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 86.34%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the firm earned $1.70 earnings per share. The firm’s revenue was down 1.3% compared to the same quarter last year. On average, equities research analysts anticipate that Zoetis Inc. will post 6.25 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is presently 34.93%.

Zoetis Profile

(Free Report)

Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish.

The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.

Zoetis originated as Pfizer’s animal health business and became an independent public company in 2013.